NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31

NEOGEN CORP

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026

$11.63−0.18 (-1.52%)

Close on Oct 19, 2026

Market cap: $2.54B
P/E (TTM): –
Dividend yield: –

NEOGEN CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-05-31	FY 2025 2025-05-31	FY 2024 2024-05-31	FY 2023 2023-05-31	FY 2022 2022-05-31	FY 2021 2021-05-31	FY 2020 2020-05-31	FY 2019 2019-05-31	FY 2018 2018-05-31	FY 2017 2017-05-31	FY 2016 2016-05-31	FY 2015 2015-05-31	FY 2014 2014-05-31	FY 2013 2013-05-31	FY 2012 2012-05-31	FY 2011 2011-05-31	FY 2010 2010-05-31
Revenue	870	895	924	822	527	468	418	414	398	358	321	283	247	208	184	173	141
Cost of Revenue	462	473	460	416	284	253	222	222	212	189	168	143	125	98	92	85	68
Gross Profit	409	421	464	406	243	215	196	192	186	169	153	140	123	109	92	88	73
Research & Development	18	21	23	26	17	16	15	13	11	10	9.89	9.58	8.33	7.78	6.64	6.83	6.26
Selling, General & Admin	412	402	383	342	167	125	114	111	105	94	87	77	71	61	52	45	40
Selling & Marketing	167	184	183	141	85	73	70	70	67	59	58	52	46	41	35	30	26
General & Administrative	245	218	200	201	83	51	44	41	38	34	29	25	24	20	17	15	13
Operating Expenses	430	1,482	405	368	184	141	129	124	116	104	97	87	79	69	59	52	46
Operating Income	-22	-1,061	59	38	59	74	68	68	70	65	56	53	43	41	34	36	27
Interest Expense	24	38	42	27	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	–	3.11	6.36	3.17	–	–	–	–	–	0.84	0.32	0.23	0.12	0.14	0.11	0.10	0.08
Other Non-Operating Income	13	-72	-73	-60	1.59	1.10	4.78	4.87	3.27	1.73	-0.87	-1.04	-0.36	0.44	0.10	-0.64	0.44
Merger & Restructuring Charges	7.00	11	3.51	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	1,069	0.60	0	0	0	0	0	0	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-1.20	0	-1.10	0.49	0	0	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-9.00	-1,133	-14	-22	60	75	72	73	73	67	56	52	43	41	34	35	27
Income Tax Expense	-1.10	-41	-4.90	0.83	12	14	13	13	10	23	19	19	15	14	11	12	9.80
Net Income incl. Noncontrolling Interests	-7.90	-1,092	-9.40	-23	48	61	59	60	63	44	37	34	28	27	22	23	–
Minority Interest in Earnings	–	–	–	–	–	–	–	0	0.07	0.18	-0.03	0.05	-0.13	-0.15	-0.12	-0.04	–
Net Income	-7.90	-1,092	-9.40	-23	48	61	59	60	63	44	37	34	28	27	23	23	18
EPS (Basic)(per share)	-0.04	-5.03	-0.04	-0.12	0.45	0.57	0.57	0.58	0.62	0.44	0.37	0.34	0.29	0.29	0.24	0.25	0.20
EPS (Diluted)(per share)	-0.04	-5.03	-0.04	-0.12	0.45	0.57	0.56	0.57	0.61	0.43	0.36	0.34	0.29	0.28	0.23	0.24	0.19
Shares Outstanding (Basic, Weighted)(shares)	218	217	217	189	108	106	105	104	103	101	100	99	97	95	94	92	90
Shares Outstanding (Diluted, Weighted)(shares)	218	217	217	189	108	107	106	105	104	102	101	100	99	97	96	95	92
EBITDA	95	-942	175	126	82	95	86	86	87	80	69	64	53	48	40	41	31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Aug 31, 2026

Profitability, TTM

Gross margin: 47.4%
Operating margin: -0.8%
Net margin: -6.3%
Return on equity, FY2026: -0.4%

Financial strength

Current ratio: 3.90
Debt to equity: 0.74
Debt to assets: 47.1%
Cash to current liabilities: 115.1%

Valuation

P/E ratio: –
Price to sales: 2.87
Price to book: 1.22
Dividend yield: –